Connect with us

COVID19

COVAXIN: Human Trials Of India’s First COVID-19 Vaccine Begin Today At AIIMS, Delhi

Anybody willing to participate in the trial can send an email to [email protected]

Published

on

NEW DELHI: India’s first coronavirus vaccine COVAXIN human trials are beginning today at the All India Institute of Medical Science (AIIMS), Delhi after its Ethics Committee gave its nod.

COVAXIN is an indigenously developed COVID-19 vaccine candidate following which country’s premier hospital is all set to begin the exercise by enrolling healthy volunteers.

The country’s top drug regulator Drug Controller General of India (DCGI) had recently given a green signal for human clinical trials for COVID-19 vaccine candidate Covaxin, which has been developed by the Hyderabad-based Bharat Biotech in collaboration with the ICMR and the National Institute of Virology (NIV).



How to participate in human trials of COVAXIN

Anybody willing to participate in the trial can send an email to [email protected] or an SMS to or call on 7428847499, he said. The institute may also put up these contact details on its website.


The DCGI has permitted two vaccines — one developed by the Bharat Biotech in collaboration with the ICMR and another one by Zydas Cadila Healthcare Ltd to go in for phase I and II human clinical trials.

The two vaccine candidates have undergone successful toxicity studies in rats, mice and rabbits and these data was submitted to DCGI following which both got clearance to start the early phase human trials early this month.


Approximately 1,000 human volunteers would be participating in the exercise for each of the two indigenously developed vaccine candidates, he had said.

The first phase of clinical trials will involve around 300 people, and the subsequent phase will add another 700, according to the earmarked hospitals.

Bharat Biotech produces billions of vaccine doses fighting infections including rotavirus and hepatitis. In 2015, the manufacturer produced the first India-made rotavirus vaccine priced at $1 (€0.89) a dose and now part of the World Health Organization’s immunization program.

Highlights:

  • AIIMS-Delhi is among the 12 sites selected by the Indian Council for Medical Research (ICMR) for conducting phase I and II human trials of Covaxin.
  • In phase I, the vaccine would be tested on 375 volunteers and a maximum of 100 of them would be from AIIMS.
  • Healthy volunteers having no comorbid conditions and without a history of COVID-19, aged more than 18 years and less than 55 years, would be eligible to participate in the randomised, double-blind, placebo-controlled clinical trial.
  • A few volunteers have already registered for the trial. AIIMS will start the screening of the individuals and evaluate their health condition from Monday (today) onwards before vaccinating them.
  • COVID-19 vaccine candidate Covaxin, developed by the Hyderabad-based Bharat Biotech in collaboration with the ICMR and the National Institute of Virology (NIV), had recently got the nod for human clinical trials from the Drugs Controller General of India (DCGI).
  • Noting that this was the first indigenous vaccine being developed by India, ICMR Director-General Dr Balram Bhargava in a letter to principal investigators of the 12 sites recently had asked them to fast-track the human clinical trial approvals stating it is one of the “top priority projects which is being monitored at the top-most level of the government”.
  • The trials have so far started in AIIMS, Patna and some more sites.

Vaccine development takes place in phased clinical trials, each with more test subjects to determine if a vaccine candidate produces the desired antibody response with a correspondingly low level of side effects.

A global race is underway to develop and mass-produce an effective vaccine against SARS-CoV-2.


There are more than 100 vaccine candidates in pre-clinical development by pharmaceutical companies, academic institutions, government agencies, and others.

According to the WHO, as of July 7, there are 17 vaccine candidates undergoing clinical trials in several countries. Although governments are pre-ordering billions of doses of promising candidates, no vaccine is expected to be approved for use over the next several months.

Continue Reading
Comments

COVID19

COVID-19: In 15 Days, Recovery Rate Improves To 67% From 63%

Presently, the total number of active corona cases in the country is 5,86,244.

Published

on

NEW DELHI: The highest recoveries from coronavirus have been reported in the country within 24 hours. A total of 51 thousand 706 people affected with coronavirus have recovered in one day which is the highest figure since the outbreak of Covid-19 pandemic in India. This has resulted in further improvement in the recovery rate which has reached 67.19 per cent in the country.

The Health and Family Welfare Ministry yesterday said, a total of 12 lakh 82 thousand 215 people have recovered from coronavirus in the country so far. It said, there has been a 63.8 per cent increase in recovered cases in the last 14 days.

The aggressive testing along with ramped up hospital infrastructure has ensured the increased recovery rate which has improved from 63 per cent to 67 per cent in two weeks.


The Ministry said that a total of 52,509 new cases of Covid-19 have been reported in the country in the past 24 hours taking the total number of cases to 19,08,254.

Presently, the total number of active corona cases in the country is 5,86,244.

In a single day, 857 deaths have been reported taking the nationwide toll to 39,795. The case fatality rate has further declined to 2.08 per cent in the country.


Meanwhile, the Indian Council of Medical Research said that a total of 2,14,84,402 tests have been conducted in the country so far.

Continue Reading

COVID19

COVID-19: India Has Now Tested Over Two Crore Samples For Coronavirus

The number of ‘Tests Per Million’ in the country has increased to over 14,850.

Published

on

NEW DELHI: In a landmark achievement, India has tested over two crore COVID-19 samples so far. The remarkable feat has been achieved by the State and Union Territories under the guidance of Centre for management of COVID-19.

India has carried out over two crore tests for detection of COVID-19 pursuant to the key strategy of “test aggressively, track efficiently and isolate and treat promptly”, the government said on Monday, hailing the milestone as a “landmark achievement”.

The objectives of testing aggressively, tracking efficiently and isolating and treating promptly are rigorously followed by States and Union Territories in terms of the guidance given by the Health Ministry.


Effective implementation of this approach has led to ramping up the testing capacity across the country and facilitated widespread COVID testing of people. With 6,61,715 samples tested in the last 24 hours, the number of Tests Per Million in the country has increased to over 14,850.

COVID testing in the country has demonstrated a steady upward trend indicating the growing testing network. In another positive development, around 24 States and Union Territories have reported higher testing per million than the national average.

On Aug 3, a record six lakh 61,715 COVID tests were done by various laboratories. This is the highest number of COVID tests conducted in the country in a single day so far.


More than 2,08,64,000 tests have been conducted in the country till now.

Starting from less than 100 tests per day, a multiple fold increase in a few months was made possible by dedicated teams of research institutions, medical colleges, testing laboratories, Ministries, airlines and postal services. Government has created robust health infrastructure for effective management of COVID-19 pandemic within a short span.

In January this year, there was only one testing laboratory for COVID-19 in India. Now, 1,356 labs are engaged in testing the COVID samples across the country. Out of the total 917 are government labs while 439 and private laboratories.

Continue Reading

COVID19

Govt Warns Against Use Of N-95 Masks With Valved Respirators

There is “inappropriate use” of N-95 masks by the public other than designated health workers.

Published

on

NEW DELHI: The Centre has written to all states and union territories warning against the use of N-95 masks with valved respirators by people, saying these do not prevent the virus from spreading out and are “detrimental” to the measures adopted for its containment.

The Director-General of Health Services (DGHS) in the Ministry of Health, in a letter to the Principal Secretaries of health and medical education of states, said it has been observed that there is “inappropriate use” of N-95 masks, particularly those with valved respirators, by the public other than designated health workers.

“…I would like to draw your attention to the advisory on the use of home-made protective cover for face and mouth available on the website of the MoHFW,” read the statement by the DGHS.


The official referred to the advisory on the use of homemade protective cover for face and mouth available on the website of the Ministry of Health.

This advisory had been issued by the central government in April, asking people to use a homemade protective cover for face and mouth, particularly when they step outside of their residences.

The advisory stressed such face covers must be washed and cleaned each day, as instructed, and stated that any used cotton cloth can be used to make this face cover.


The colour of the fabric does not matter but one must ensure that the fabric is washed well in boiling water for five minutes and dried well before making the face cover.

It is to bring to your knowledge that the use of valved respirator N-95 masks is detrimental to the measures adopted for preventing the spread of coronavirus as it does not prevent the virus from escaping out of the mask. In view of the above, I request you to instruct all concerned to follow the use of face/mouth cover and prevent inappropriate use of N-95 masks,” DGHS Rajiv Garg said in the letter.

Continue Reading

Most Read This Month

error: Content on this news portal is protected!